These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

292 related items for PubMed ID: 38609654

  • 1. PARP1 promotes EGFR-TKI drug-resistance via PI3K/AKT pathway in non-small-cell lung cancer.
    Xu X, Liu Y, Gong Q, Ma L, Wei W, Zhao L, Luo Z.
    Cancer Chemother Pharmacol; 2024 Aug; 94(2):209-221. PubMed ID: 38609654
    [Abstract] [Full Text] [Related]

  • 2. Role of PARP1-mediated autophagy in EGFR-TKI resistance in non-small cell lung cancer.
    Zhang Z, Lian X, Xie W, Quan J, Liao M, Wu Y, Yang ZZ, Wang G.
    Sci Rep; 2020 Dec 01; 10(1):20924. PubMed ID: 33262410
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Polyphyllin II Restores Sensitization of the Resistance of PC-9/ZD Cells to Gefitinib by a Negative Regulation of the PI3K/Akt/mTOR Signaling Pathway.
    Zheng R, Jiang H, Li J, Liu X, Xu H.
    Curr Cancer Drug Targets; 2017 Dec 01; 17(4):376-385. PubMed ID: 28093061
    [Abstract] [Full Text] [Related]

  • 5. Tyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer.
    Yoshida T, Zhang G, Smith MA, Lopez AS, Bai Y, Li J, Fang B, Koomen J, Rawal B, Fisher KJ, Chen YA, Kitano M, Morita Y, Yamaguchi H, Shibata K, Okabe T, Okamoto I, Nakagawa K, Haura EB.
    Clin Cancer Res; 2014 Aug 01; 20(15):4059-4074. PubMed ID: 24919575
    [Abstract] [Full Text] [Related]

  • 6. MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer.
    Li B, Ren S, Li X, Wang Y, Garfield D, Zhou S, Chen X, Su C, Chen M, Kuang P, Gao G, He Y, Fan L, Fei K, Zhou C, Schmit-Bindert G.
    Lung Cancer; 2014 Feb 01; 83(2):146-53. PubMed ID: 24331411
    [Abstract] [Full Text] [Related]

  • 7. The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens.
    Wu YY, Wu HC, Wu JE, Huang KY, Yang SC, Chen SX, Tsao CJ, Hsu KF, Chen YL, Hong TM.
    J Exp Clin Cancer Res; 2019 Jul 01; 38(1):282. PubMed ID: 31262325
    [Abstract] [Full Text] [Related]

  • 8. Targeting EHMT2 reverses EGFR-TKI resistance in NSCLC by epigenetically regulating the PTEN/AKT signaling pathway.
    Wang L, Dong X, Ren Y, Luo J, Liu P, Su D, Yang X.
    Cell Death Dis; 2018 Jan 26; 9(2):129. PubMed ID: 29374157
    [Abstract] [Full Text] [Related]

  • 9. miR-223 enhances the sensitivity of non-small cell lung cancer cells to erlotinib by targeting the insulin-like growth factor-1 receptor.
    Zhao FY, Han J, Chen XW, Wang J, Wang XD, Sun JG, Chen ZT.
    Int J Mol Med; 2016 Jul 26; 38(1):183-91. PubMed ID: 27177336
    [Abstract] [Full Text] [Related]

  • 10. Estrogen receptor β1 activation accelerates resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in non-small cell lung cancer.
    Fu S, Liu C, Huang Q, Fan S, Tang H, Fu X, Ai B, Liao Y, Chu Q.
    Oncol Rep; 2018 Mar 26; 39(3):1313-1321. PubMed ID: 29328407
    [Abstract] [Full Text] [Related]

  • 11. [Molecular mechanism of erlotinib resistance in epidermal growth factor receptor mutant non-small cell lung cancer cell line H1650].
    Han R, Wang X, Zhong D, Zhao J, Chen Z, Sun L, Wang J, Zhang J.
    Zhongguo Fei Ai Za Zhi; 2012 Dec 26; 15(12):689-93. PubMed ID: 23249714
    [Abstract] [Full Text] [Related]

  • 12. Targeting mTOR to overcome epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer cells.
    Fei SJ, Zhang XC, Dong S, Cheng H, Zhang YF, Huang L, Zhou HY, Xie Z, Chen ZH, Wu YL.
    PLoS One; 2013 Dec 26; 8(7):e69104. PubMed ID: 23874880
    [Abstract] [Full Text] [Related]

  • 13. Lymecycline reverses acquired EGFR-TKI resistance in non-small-cell lung cancer by targeting GRB2.
    Chen Y, Wu J, Yan H, Cheng Y, Wang Y, Yang Y, Deng M, Che X, Hou K, Qu X, Zou D, Liu Y, Zhang Y, Hu X.
    Pharmacol Res; 2020 Sep 26; 159():105007. PubMed ID: 32561477
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of histone deacetylases sensitizes EGF receptor-TK inhibitor-resistant non-small-cell lung cancer cells to erlotinib in vitro and in vivo.
    Yu W, Lu W, Chen G, Cheng F, Su H, Chen Y, Liu M, Pang X.
    Br J Pharmacol; 2017 Oct 26; 174(20):3608-3622. PubMed ID: 28749535
    [Abstract] [Full Text] [Related]

  • 15. Rab25 promotes erlotinib resistance by activating the β1 integrin/AKT/β-catenin pathway in NSCLC.
    Wang J, Zhou P, Wang X, Yu Y, Zhu G, Zheng L, Xu Z, Li F, You Q, Yang Q, Zhuo W, Sun J, Chen Z.
    Cell Prolif; 2019 May 26; 52(3):e12592. PubMed ID: 30848009
    [Abstract] [Full Text] [Related]

  • 16. Combined Erlotinib and Cetuximab overcome the acquired resistance to epidermal growth factor receptors tyrosine kinase inhibitor in non-small-cell lung cancer.
    Wang M, Zhao J, Zhang LM, Li H, Yu JP, Ren XB, Wang CL.
    J Cancer Res Clin Oncol; 2012 Dec 26; 138(12):2069-77. PubMed ID: 22821179
    [Abstract] [Full Text] [Related]

  • 17. LMNA Reduced Acquired Resistance to Erlotinib in NSCLC by Reversing the Epithelial-Mesenchymal Transition via the FGFR/MAPK/c-fos Signaling Pathway.
    Hu C, Zhou A, Hu X, Xiang Y, Huang M, Huang J, Yang D, Tang Y.
    Int J Mol Sci; 2022 Oct 31; 23(21):. PubMed ID: 36362025
    [Abstract] [Full Text] [Related]

  • 18. Kaempferol potentiates the sensitivity of pancreatic cancer cells to erlotinib via inhibition of the PI3K/AKT signaling pathway and epidermal growth factor receptor.
    Zhang Z, Guo Y, Chen M, Chen F, Liu B, Shen C.
    Inflammopharmacology; 2021 Oct 31; 29(5):1587-1601. PubMed ID: 34322786
    [Abstract] [Full Text] [Related]

  • 19. JAK2 inhibitor TG101348 overcomes erlotinib-resistance in non-small cell lung carcinoma cells with mutated EGF receptor.
    Zhang FQ, Yang WT, Duan SZ, Xia YC, Zhu RY, Chen YB.
    Oncotarget; 2015 Jun 10; 6(16):14329-43. PubMed ID: 25869210
    [Abstract] [Full Text] [Related]

  • 20. Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.
    Gadgeel SM, Wozniak A.
    Clin Lung Cancer; 2013 Jul 10; 14(4):322-32. PubMed ID: 23332287
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.